Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Johnson & Johnson (JNJ : NYSE)
 
 • Company Description   
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

Number of Employees: 155,800

 
 • Price / Volume Information   
Yesterday's Closing Price: $155.00 Daily Weekly Monthly
20 Day Moving Average: 8,015,286 shares
Shares Outstanding: 2,604.29 (millions)
Market Capitalization: $403,664.31 (millions)
Beta: 0.54
52 Week High: $186.69
52 Week Low: $150.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.67% -1.49%
12 Week -13.31% -19.67%
Year To Date -12.26% -17.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE JOHNSON & JOHNSON PLZ
-
NEW BRUNSWICK,NJ 08933
USA
ph: 732-524-0400
fax: 732-214-0332
None http://www.jnj.com
 
 • General Corporate Information   
Officers
J. Duato - Chief Executive Officer & Chairman
J. J. Wolk - Chief Financial Officer
R. J. Decker Jr. - Controller and Chief Accounting Officer
D. Adamczyk - Director
M. C. Beckerle - Director

Peer Information
Johnson & Johnson (AGN.)
Johnson & Johnson (ABBV)
Johnson & Johnson (NVO)
Johnson & Johnson (LLY)
Johnson & Johnson (RHHBY)
Johnson & Johnson (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 478160104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 04/18/23
Share - Related Items
Shares Outstanding: 2,604.29
Most Recent Split Date: 6.00 (2.00:1)
Beta: 0.54
Market Capitalization: $403,664.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.92%
Current Fiscal Quarter EPS Consensus Estimate: $2.51 Indicated Annual Dividend: $4.52
Current Fiscal Year EPS Consensus Estimate: $10.50 Payout Ratio: 0.44
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: -0.01
Estmated Long-Term EPS Growth Rate: 5.53% Last Dividend Paid: 02/17/2023 - $1.13
Next EPS Report Date: 04/18/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 14.76
Trailing 12 Months: 15.26
PEG Ratio: 2.67
Price Ratios
Price/Book: 5.27
Price/Cash Flow: 11.91
Price / Sales: 4.25
EPS Growth
vs. Year Ago Period: 10.33%
vs. Previous Quarter: -7.84%
Sales Growth
vs. Year Ago Period: -4.43%
vs. Previous Quarter: -0.36%
ROE
03/31/23 - 35.76
12/31/22 - 35.37
09/30/22 - 36.14
ROA
03/31/23 - 15.05
12/31/22 - 14.86
09/30/22 - 14.88
Current Ratio
03/31/23 - 0.99
12/31/22 - 1.43
09/30/22 - 1.42
Quick Ratio
03/31/23 - 0.77
12/31/22 - 1.18
09/30/22 - 1.17
Operating Margin
03/31/23 - 28.48
12/31/22 - 27.59
09/30/22 - 27.92
Net Margin
03/31/23 - 18.90
12/31/22 - 19.95
09/30/22 - 19.21
Pre-Tax Margin
03/31/23 - 22.88
12/31/22 - 23.28
09/30/22 - 21.33
Book Value
03/31/23 - 29.39
12/31/22 - 28.53
09/30/22 - 29.04
Inventory Turnover
03/31/23 - 2.67
12/31/22 - 2.81
09/30/22 - 2.84
Debt-to-Equity
03/31/23 - 0.35
12/31/22 - 0.37
09/30/22 - 0.37
Debt-to-Capital
03/31/23 - 25.93
12/31/22 - 27.01
09/30/22 - 27.03
 

Powered by Zacks Investment Research ©